{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:30:27Z","timestamp":1794562227639,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ygyno.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:04:05Z","timestamp":1779152645000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III\u2013IVA cervical cancer in the United States"],"prefix":"10.1016","volume":"210","author":[{"given":"Sarah","family":"Brand-Wiita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Jhih","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Heng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Muston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Szamreta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Duska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.05.001_bb0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.05.001_bb0010","series-title":"Cancer Stat Facts: Cervical Cancer","author":"National Cancer Institute (NIH)","year":"2025"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0015","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.05.001_bb0020","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","article-title":"Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials","volume":"26","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.001_bb0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5152\/dir.2020.19437","article-title":"Cervical cancer recurrence \u2013 can we predict the type of recurrence?","volume":"26","author":"Linhares Moreira","year":"2020","journal-title":"Diagn. Interv. Radiol."},{"key":"10.1016\/j.ygyno.2026.05.001_bb0030","series-title":"Clinical Study Report: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18\/ENGOT-cx11\/GOG-3047)","author":"MSD","year":"2025"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0035","series-title":"ICER's Reference Case for Economic Evaluations: Principles and Rationale","author":"Institute for Clinical and Economic Review (ICER)","year":"2025"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0040","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40487-024-00311-5","article-title":"Cost-effectiveness of pembrolizumab as first-line treatment in patients with persistent, recurrent, or metastatic cervical cancer in the United States","volume":"13","author":"Monk","year":"2025","journal-title":"Oncol Ther."},{"key":"10.1016\/j.ygyno.2026.05.001_bb0050","series-title":"TA939: Pembrolizumab Plus Chemotherapy with or without Bevacizumab for Persistent, Recurrent or Metastatic Cervical Cancer","author":"National Institute for Health and Care Excellence (NICE)","year":"2023"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0055","series-title":"TA885: Pembrolizumab Plus Chemotherapy with or without Bevacizumab for Persistent, Recurrent or Metastatic Cervical Cancer","author":"National Institute for Health and Care Excellence (NICE)","year":"2023"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0060","series-title":"Pembrolizumab Plus Chemotherapy with or without Bevacizumab for Persistent, Recurrent or Metastatic Cervical Cancer","author":"Canada'\u2019s Drug Agency (CDA)","year":"2023"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0065","author":"MSD","year":"2023"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0070","series-title":"2021 National Medicare Severity Diagnosis Related Groups (MS-DRG)","author":"AHRQ HCUPnet","year":"2021"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0075","author":"MSD","year":"2025"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0080","series-title":"AnalySource\u2014Premier Drug Pricing Services","author":"AnalySource","year":"2024"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0085","series-title":"Search the Physician Fee Schedule","author":"Centers for Medicare & Medicaid Services (CMS)","year":"2024"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0090","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijrobp.2017.09.004","article-title":"Evaluation of delivery costs for external beam radiation therapy and brachytherapy for locally advanced cervical cancer using time-driven activity-based costing","volume":"100","author":"Bauer-Nilsen","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2026.05.001_bb0095","series-title":"Physician Fee Schedule","author":"Centers for Medicare & Medicaid Services (CMS)","year":"2024"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.03.022","article-title":"An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations","volume":"146","author":"Salani","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.001_bb0105","series-title":"CancerMPact\u00ae Treatment Architecture. Cervical Cancer","author":"Oracle Life Sciences","year":"2024"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0110","series-title":"National Medicare Severity Diagnosis Related Groups (MS-DRG)","author":"Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (AHRQ HCUPnet)","year":"2021"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0115","doi-asserted-by":"crossref","first-page":"75s","DOI":"10.1200\/JOP.2011.000469","article-title":"Health care costs for patients with cancer at the end of life","volume":"8","author":"Chastek","year":"2012","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.ygyno.2026.05.001_bb0120","series-title":"United States Life Tables, 2022","author":"Arias","year":"2025"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0125","series-title":"Value Assessment Framework","author":"Institute for Clinical and Economic Review (ICER)","year":"2023"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0130","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2025.36.e106","article-title":"International cost-effectiveness analysis of chemoradiotherapy plus pembrolizumab for locally advanced cervical cancer","volume":"36","author":"Liu","year":"2025","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.001_bb0135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.0033","article-title":"Cost-effectiveness of pembrolizumab with chemoradiotherapy for locally advanced cervical cancer","volume":"8","author":"Courtney","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0140","series-title":"Cervical Cancer Version 3","author":"Network NCC","year":"2026"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0145","series-title":"Survival Analysis Report for KNA18 FA, FIGO III-IVA","author":"MSD","year":"2025"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0150","series-title":"HCUP Methods Series: Methods for Calculating Patient Travel Distance to Hospital in HCUP Data","author":"Agency for Healthcare and Research Quality","year":"2024"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0155","series-title":"United States Retirement Age - Women","author":"Trading Economics","year":"2022"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0160","series-title":"Table B-3. Average hourly and Weekly Earnings of All Employees on Private Nonfarm Payrolls by Industry Sector, Seasonally Adjusted","author":"U.S Bureau of Labor Statistics (BLS)","year":"2024"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0165","series-title":"Table 4. Employed Persons Working and Time Spent Working on Days Worked by Full- and part-time Status and Sex, Jobholding Status, Educational Attainment, and Day of Week, 2023 Annual Averages","author":"U.S Bureau of Labor Statistics (BLS)","year":"2023"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0170","series-title":"Table A-1: Current and Real (Constant 1982\u20131984 Dollars) Earnings for all Employees on Private Nonfarm Payrolls, Seasonally Adjusted; Category: Average Weekly Hours","author":"U.S Bureau of Labor Statistics (BLS)","year":"2024"},{"key":"10.1016\/j.ygyno.2026.05.001_bb0175","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamaoncol.2020.1475","article-title":"Assessment of parking fees at national cancer institute-designated cancer treatment centers","volume":"6","author":"Lee","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2026.05.001_bb0180","series-title":"AAA Your Driving Costs Calculator","author":"The American Automobile Association (AAA)","year":"2026"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582601975X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582601975X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:19:48Z","timestamp":1794561588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582601975X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"alternative-id":["S009082582601975X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.05.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III\u2013IVA cervical cancer in the United States","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}